Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00084214
Status:
COMPLETED
Last Update Posted:
2014-03-06
First Post:
2004-06-09
Brief Title:
STA-4783Paclitaxel or Paclitaxel Alone in Melanoma
Sponsor:
Synta Pharmaceuticals Corp
Organization:
Synta Pharmaceuticals Corp
Study Overview
Official Title:
A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients
Detailed Description:
STA-4783 is a taxane potentiator enhancing the effect of antitumor response of paclitaxel In an attempt to improve efficacy paclitaxel is sometimes used in combination with other anticancer agents When paclitaxel is combined with other anticancer agents although response rate is usually increased side effects are usually increased as well There is an urgent need for agents that can enhance the antitumor effects of paclitaxel without further increasing undesirable side effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None